Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
Rajesh ValanparambilJennifer CarlisleSusanne LindermanAkil AktharRalph Linwood MillettLilin LaiAndres ChangAshley McCookJeffrey SwitchenkoTahseen NastiManpreet SainiAndreas Wieland Andreas WielandKelly ManningMadison EllisKathryn MooreStephanie FosterKatharine FloydMeredith Davis-GardnerVenkata Viswanadh EdaraMit PatelConor SteurAjay NookaFelicia GreenMargaret JohnsFiona O BreinUma ShanmugasundaramVeronika ZarnitsynaHasan AhmedLindsay NyhoffGrace MantusMichael GarettSrilatha EdupugantiMadhusmita BehraRustom AntiaJens WrammertMehul S SutharMadhav DhodapkarSuresh RamalingamRafi AhmedPublished in: medRxiv : the preprint server for health sciences (2022)
Binding and live-virus neutralizing antibody titers to SARS-CoV-2 mRNA vaccines in NSCLC patients were lower than the healthy vaccinees, with significantly lower live-virus neutralization of B.1.617.2 (Delta), and more importantly, the B.1.1.529 (Omicron) variant compared to the wild-type strain. These data highlight the concern for cancer patients given the rapid spread of SARS-CoV-2 Omicron variant.
Keyphrases
- sars cov
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- respiratory syndrome coronavirus
- prognostic factors
- peritoneal dialysis
- wild type
- electronic health record
- advanced non small cell lung cancer
- dna methylation
- transcription factor
- dengue virus
- aedes aegypti